Results 191 to 200 of about 34,133,693 (246)

Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists. [PDF]

Vision (Basel)
Lixi F, Troisi M, Calabresi V, Giagoni A, Rossi C, Timofte-Zorila MM, Tarași TC, Vitiello L, Tomi MI, Gheorghe AG, Coco G, Lanzolla G, Giannaccare G.   +12 more
europepmc   +1 more source

Bowel Obstruction/Ileus Associated With the Use of Glucagon‐Like Peptide‐1 Receptor Agonists: A Nationwide Database Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The association between glucagon‐like peptide‐1 receptor agonist (GLP‐1RA) use and the development of bowel obstruction/ileus remains unclear, and evidence for specific bowel obstruction/ileus subtypes remains limited. We examined the association between GLP‐1RA use and the incidence of bowel obstruction/ileus subtypes across different ...
Yuichiro Matsuo, Akira Okada, Takashi Sakamoto, Hideo Yasunaga   +3 more
wiley   +1 more source

State‐Level Variation in Glucagon‐Like Peptide‐1 Receptor Agonists Fills and Spending by Obesity Prevalence, 2023

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Tamkeen Khan, Stavros Tsipas, Fleetwood Loustalot, Lindsay Zasadzinski, Klodiana Myftari, Alyson B. Goodman, Gregory D. Wozniak   +6 more
doaj   +1 more source

Oral Glucagon-Like Peptide-1 Receptor Agonists for Preventing Cardiorenal Complications. [PDF]

Curr Cardiol Rep
Odeleye V, Singh N, Gautam S, Shannon E, Bibb WM, McClure M, Paul TK.   +6 more
europepmc   +1 more source

Retatrutide‐Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To further characterise the effects of retatrutide on cardiometabolic risk, lipoprotein and inflammatory biomarkers were assessed post hoc in phase 2 trials of adults with obesity/overweight with or without type 2 diabetes (T2D). Materials and Methods Data were analysed from two randomised, double‐blind, placebo‐controlled phase 2 trials.
Giacomo Ruotolo, Charles Harris, Yanzhu Lin, Jonathan M. Wilson, Valentina Pirro, Kevin L. Duffin, Melissa K. Thomas, Mark L. Hartman, Ciara O' Neill, Tamer Coskun, Zvonko Milicevic, Axel Haupt, Naveed Sattar, Stephen J. Nicholls   +13 more
wiley   +1 more source

Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study. [PDF]

Diabetes Obes Metab
Engström A, Svanström H, Hviid A, Eliasson B, Gudbjörnsdottir S, Wintzell V, Hveem K, Jonasson C, Melbye M, Ueda P, Pasternak B.   +10 more
europepmc   +1 more source

Acute Contractile Effects of Glucagon-like-Peptide-1 Receptor Agonists in the Human Heart. [PDF]

Pharmaceutics
Neumann J, Kirchhefer U, Hofmann B, Gergs U.   +3 more
europepmc   +1 more source

Liraglutide and Βeta‐Cell Function in Young Adults With Long‐Standing Type 1 Diabetes and Residual C‐Peptide: A Blinded, Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the effect of liraglutide on residual beta‐cell function in adults with long‐standing type 1 diabetes (T1D) and detectable C‐peptide. Materials and Methods In this randomized, blinded, placebo‐controlled trial, 18 adults with T1D duration ≥ 5 years and detectable fasting C‐peptide were assigned to liraglutide or placebo for 52 
José Caballero‐Corbalán, Per Lundkvist, Daniel Espes, Per‐Ola Carlsson   +3 more
wiley   +1 more source

Accumulation and attenuation of cardiovascular benefit with glucagon-like peptide 1 receptor agonists. [PDF]

BMJ Med
Batty JA, Del Toro T, Hall M.
europepmc   +1 more source

Oleanolic Acid‐Enriched Olive Oil Attenuates Kidney Function Decline in Patients With Type 2 Diabetes: Results From the OLTRAD Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Chronic kidney disease (CKD) is a major complication of type 2 diabetes mellitus (T2DM), driven in part by oxidative stress and the accumulation of advanced glycation end products (AGEs). Oleanolic acid (OA), a natural triterpene present in olive‐derived matrices, may modulate AGE metabolism.
Aída García‐González, Alejandro Matamoros‐Domínguez, Juan Manuel Espinosa‐Cabello, Gisela Pérez‐Muñoz, Manuel Jesús León Aranda, María Del Carmen Roque‐Cuellar, Silvia García‐Rey, Andrés Jiménez‐Sánchez, Antonio Jesús Martínez‐Ortega, Miguel Ángel Mangas‐Cruz, Isabel Cerrillo, Javier S. Perona, Pedro Pablo García‐Luna, Elena María Yubero‐Serrano, José María Castellano   +14 more
wiley   +1 more source